From concept to reality: CAR‐T therapy as a glimmer of hope for systemic lupus erythematosus patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From concept to reality: CAR‐T therapy as a glimmer of hope for systemic lupus erythematosus patients
Authors
Keywords
-
Journal
International Journal of Rheumatic Diseases
Volume 26, Issue 11, Pages 2137-2140
Publisher
Wiley
Online
2023-11-01
DOI
10.1111/1756-185x.14871
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management
- (2023) Dario Roccatello et al. DRUGS
- OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS
- (2023) J. Taubmann et al. ANNALS OF THE RHEUMATIC DISEASES
- New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review
- (2023) Renaud Felten et al. JOINT BONE SPINE
- CD19-targeted CAR T cells in refractory antisynthetase syndrome
- (2023) Fabian Müller et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
- (2023) Eric F Morand et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
- (2023) Michelle Petri et al. LANCET
- Chimeric receptors broaden the therapeutic landscape for autoimmune disease
- (2023) Terri H. Finkel et al. Nature Reviews Rheumatology
- From bench to bedside: the history and progress of CAR T cell therapy
- (2023) Aroshi Mitra et al. Frontiers in Immunology
- Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
- (2023) Rongxiu Huo et al. Journal of Inflammation Research
- Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
- (2022) Eric F Morand et al. Lancet Rheumatology
- Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus
- (2022) Nasim Bolouri et al. INFLAMMATION RESEARCH
- OP0279 CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS
- (2022) G. Schett et al. ANNALS OF THE RHEUMATIC DISEASES
- Management of non‐renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements
- (2022) Nuntana Kasitanon et al. International Journal of Rheumatic Diseases
- Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
- (2022) Richard Furie et al. Clinical Journal of the American Society of Nephrology
- Medications impact different aspects of the quality of life of patients with systemic lupus erythematosus
- (2022) Khai Pang Leong et al. International Journal of Rheumatic Diseases
- Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
- (2022) Andreas Mackensen et al. NATURE MEDICINE
- CAR-T cell therapy: current limitations and potential strategies
- (2021) Robert C. Sterner et al. Blood Cancer Journal
- CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
- (2021) Dimitrios Mougiakakos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
- (2020) Xuexiao Jin et al. Cellular & Molecular Immunology
- Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
- (2019) Rita Kansal et al. Science Translational Medicine
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started